Endacea
About
Enadcea is developing L-97-1: an adenosine receptor antagonist for treatment of sepsis and acute renal injury, and an immunotherapy for cancer.
Powered By GrowthZone
Our Story
Why First Flight?
Impact Reports
Meet Our Team
Board of Directors
Meet Our Navigators
Meet Our Resident Companies
Our Programs
2024/25 FAST SBIR Funding Program
BARDA DRIVe: Health Security Innovation Funding
Business Incubator
Captain's Circle
Itineraries: Science Talk
LiftOff: Strategic Non-dilutive Funding
Navigators: Advisors and Business Mentoring
Pilots Lounge
Propeller Pre-Accelerator: Finding the Business Value in New Ideas
Test Flight: Pitch Practice
WheelsUP Accelerator
Wingspan